Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK buys full rights to make COVID, influenza vaccines from CureVac
02:26am, Wednesday, 03'rd Jul 2024
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euro
CDC Narrows Age Recommendation for Use of RSV Vaccine
12:20pm, Friday, 28'th Jun 2024
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
01:14pm, Thursday, 27'th Jun 2024
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
Biotech Stock Slips on CDC Buzz
10:48am, Thursday, 27'th Jun 2024
British biotech stock GSK plc (NYSE:GSK) is trading lower, though it pared its steeper losses today, down 1% at $38.49 at last glance after earlier sliding as much as 7%.
Here's Why GSK (GSK) is a Strong Value Stock
10:40am, Thursday, 27'th Jun 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK and Moderna slide on RSV vaccine CDC updates
04:00am, Thursday, 27'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, f
GSK stock falls more at London open following RSV vaccination news
03:58am, Thursday, 27'th Jun 2024
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated aga
GSK plummets as US restricts RSV vaccine
03:40am, Thursday, 27'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on
GSK slides 6% after US CDC narrows scope of RSV shots
03:40am, Thursday, 27'th Jun 2024
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
04:29pm, Wednesday, 26'th Jun 2024
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinate
US advisers to consider RSV shots as GSK looks to keep market lead
06:13am, Wednesday, 26'th Jun 2024
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles riva
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
10:40am, Monday, 24'th Jun 2024
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:55am, Monday, 24'th Jun 2024
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GSK 100% backs London listing, says boss
05:02am, Friday, 21'st Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
01:44pm, Tuesday, 18'th Jun 2024
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
